GoBroad Healthcare — A CAR-T Therapy Pioneer in China
August 17, 2026
As one of China's leading centers for CAR-T cell therapy, GoBroad Healthcare Group focuses on relapsed/refractory blood cancers, combining CAR-T with stem cell transplantation to raise response rates in the hardest cases.
A Pioneer in CAR-T Cell Therapy
GoBroad Healthcare Group (高博医疗) is one of the pioneers applying CAR-T cell therapy for hematologic malignancies in China. CAR-T takes the patient's own T immune cells, genetically engineers them to recognize and destroy cancer cells, then infuses them back into the body.
GoBroad focuses on the hardest patient group: relapsed or refractory acute leukemia, lymphoma and multiple myeloma, where conventional methods have failed.
A Strategy for Refractory Cases
GoBroad's strength is combining multiple weapons in a single protocol:
- CAR-T combined with salvage chemotherapy to raise response rates.
- CAR-T bridging to stem cell transplant to deepen remission in high-risk patients.
- A dual transplant strategy (autologous followed by allogeneic) in selected cases.
- Multiple CAR-T lines targeting different antigens such as CD19 and CD22 for blood cancers.
Why the CAR-T Advantage Matters
- It opens treatment for patients who have run out of options with standard protocols.
- Experience managing CAR-T side effects (cytokine storm, neurotoxicity) accumulated from large case volumes.
- Tied to clinical research, giving patients access to next-generation therapies.
For blood cancer patients unresponsive to conventional treatment, GoBroad's deep CAR-T capability is a major reason to consider treatment here.
Related Images
